What's new

What's New

12 | May | 2020

News May 12

No Patient Left Behind

Many of the world’s biggest companies and brightest minds are totally focused on a COVID-19 treatment – vaccine.

At Biomere, we are personally invested in your drug discovery efforts aimed at filling the drug development pipeline with new and innovative therapies.

Everyone has a role to play and we know ours. We are staying the course, focused on what we do best.

Leave no drug behind. Leave no patient behind.

Biomere Logo

27 | Apr | 2020

Empty open Pills Bottle isolated on white background. 3d illustr

No Drug Left Behind

We are personally invested in your efforts to continue the flow of therapies to those in need. Some of the worlds’ best companies are totally focused on a treatment – vaccine.

Everyone has a role to play and we know where ours is. No less important, but not working on COVID-19. We are staying on course, focused on what we do best.

Leave no drug behind. Leave no patient behind.

Biomere Logo

24 | Mar | 2020

COVID 19

COVID-19 Vaccine Receives Approval in China to Begin Human Trials

March 22, 2020 —A recombinant novel coronavirus vaccine candidate (Ad5-nCoV), developed by CanSino Biologics Inc. and China’s Academy of Military Medical Sciences, received Chinese regulatory approval to start human trials against COVID-19 on March 22, 2020

Results from preclinical animal studies of Ad5-nCoV show that the vaccine candidate induces strong immune responses in animal models. Preclinical animal safety studies demonstrate a good safety profile supporting clinical development. Multiple vaccines for the novel coronavirus (COVID-19) are expected to complete preclinical research in April and enter clinical trials in China, NMPA officials declared at a press conference on March 17, 2020.

In response to the outbreak of coronavirus (COVID-19), JOINN assembled a team of internal experts to develop study designs tailored to evaluate different types of novel therapies against COVID-19. We have established clinical sample analysis centers in Wuhan to support clinical trials. JOINN participated in the safety assessment of most anti-SARS-CoV-2 drugs in China, including DNA vaccines, mRNA vaccines, recombinant protein-based vaccines, peptide vaccines, inactivated virus vaccines and other drugs such as antibodies, stem-cell therapy drugs, etc. Most drugs are still in the pre-clinical stage, some have already been submitted to the regulatory department of the NMPA (National Medical Products Administration) of China.

About Joinn

Founded in 1995, JOINN Laboratories (JOINN, SH603127) is China’s first private nonclinical CRO. JOINN subsidiaries are located in Beijing, Suzhou, Chongqing, and Wuzhou (GuangXi Province) in China, and Richmond (CA) and Worcester (MA) in the United States. JOINN is CNAS/ILAC-MRA accredited (China National Accreditation Service for Conformity Assessment/International Laboratory Accreditation Cooperation-Mutual Recognition Arrangement), AAALAC accredited (Association for Assessment & Accreditation of Lab Animal Care International) and OLAW accredited, and is NMPA (CFDA), US FDA, OECD and Ko-rean MFDS GLP certified/inspected/compliant. JOINN employs 1500+ pharmaceutical professionals and provides services from early-stage R&D to clinical trials and to post-approval pharmacovigilance, tailored to the sponsor’s needs.

JOINN has extensive experience on anti-virus drug safety assessment. We have participated in the drug R & D and safety assessment of SARS, H5N1, H1N1, H7N9 and Ebola virus. In response to the outbreak of coronavirus (COVID-19), JOINN developed a green channel for rapid response to antivirus non-clinical and clinical requests. We can help sponsors to communicate with local regulatory authorities, accelerating antivirus therapy development.

For the full report with language translation, see here.